In a strategic move, Sphere Fluidics has officially rebranded as Sphere Bio, marking a significant shift in its business trajectory. The company, which was established in 2010, has evolved from a pioneer in droplet-based microfluidics to a leading provider of integrated life sciences tools and solutions. This transformation reflects the company's expanded market focus and growth potential in emerging research areas. Over the years, Sphere Bio has garnered international recognition, serving over 400 clients worldwide, including collaborations with seven of the top ten global pharmaceutical companies. The rebranding underscores the company's commitment to addressing complex industry challenges through innovative single-cell analysis platforms and assays, aiming to revolutionize life science research.

The rebranding initiative comes at a pivotal time for Sphere Bio, following substantial operational scaling and commercial expansion over the past two years. The company has invested heavily in developing cutting-edge technologies that streamline single-cell functional analysis workflows, significantly reducing project timelines. The Cyto-Mine® platform, a flagship product, exemplifies this innovation, offering unparalleled efficiency and precision in cell isolation and analysis. With the introduction of the next-generation Cyto-Mine Chroma platform, Sphere Bio is poised to further enhance its offerings and cater to a broader spectrum of biotherapeutic applications.

At the heart of Sphere Bio's success lies its proprietary picodroplet technology, which enables ultra-high throughput functional analysis of live cells. This technology has been instrumental in driving the company's growth and positioning it as a leader in the life sciences sector. The company's portfolio of tools and solutions is designed to meet the evolving needs of researchers, facilitating more efficient and cost-effective scientific discovery. By continuously expanding its product range and global market presence, Sphere Bio aims to empower researchers with the resources they need to achieve groundbreaking advancements in their fields.

Dale Levitzke, CEO of Sphere Bio, emphasized the significance of the rebranding: "This new identity sets the stage for an exciting future, reflecting our capabilities as a provider of integrated life sciences solutions. It symbolizes our growth and forward-looking approach, while maintaining strong brand recognition." Claire Cox, Director of Global Marketing, added, "Our solutions enable researchers to think big in their work. We are dedicated to evolving alongside our customers, providing them with the best tools to accelerate scientific discovery."

The rebranding signifies a transformative phase for Sphere Bio, aligning its identity with its strategic vision. As the company looks ahead to 2025, it remains committed to delivering innovative solutions that address the dynamic needs of the life sciences industry. Through continuous evolution and expansion, Sphere Bio aims to solidify its position as a key player in advancing scientific research and development.